WGRX is showing early revenue traction but remains deeply unprofitable. The sequential growth in pharmacy revenue and guidance for Q2 are incremental positives, but the company has terminated two M&A targets and relies on partnerships still in development. Given this ticker's history of extreme moves (+32% and -34% following recent neutral reports), traders should expect high volatility, but the fundamental story is still unproven at scale.
Price Chart
Executive Summary
Wellgistics Health reported Q1 2026 revenue of $0.929M, up 91% sequentially from $0.486M in Q4 2025, and reduced its net operating loss to $7.742M from $32.430M a year ago. Management guided Q2 2026 revenue to $1.775M and highlighted several growth initiatives including a Kare Pharmtech JV providing access to 200,000+ patient lives and a planned August 2026 app launch with NFL Alumni Health. The sequential revenue growth is a positive sign, but the company still operates at a steep loss, and historical volatility on this ticker is extreme.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $0.929M, up 91% sequentially from $0.486M in Q4 2025.
- Net operating loss of $7.742M in Q1 2026, improved from $32.430M in Q1 2025.
- Net operating loss per share of $0.07 on 104.6M weighted shares outstanding.
- Q2 2026 revenue guidance of $1.775M, with $0.86M already recognized through May 18.
- Wellgistics Pharmacy monthly revenue grew from ~$0.1M (Nov 2025) to ~$0.6M (Apr 2026).
- Terminated non-binding LOIs with Neuritek and WellCare.
- Completed Kare Pharmtech JV for telepharmacy capabilities and 200,000+ patient access.
- Targeted August 2026 launch of 'Health Lives Here' app with NFL Alumni Health.
Financial Impact
Revenue doubled sequentially to $0.929M, but operating loss remains high at $7.742M. Q2 guidance implies continued growth to $1.775M.
Risk Factors
- Still generating massive net losses relative to revenue — operating loss is 8.3x revenue.
- Q2 guidance is a projection, not a hard commitment, and may miss if partnerships delay.
- Sharp dilution: shares outstanding doubled YoY from 51.9M to 104.6M.
- Terminated LOIs suggest deal pipeline is not converting.
- Nasdaq compliance risk for a $22M market cap micro-cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-024454 |
| Exhibit: ex99-1.htm | 0001493152-26-024454 |
| Document: 0001493152-26-024454-index-headers.html | 0001493152-26-024454 |
| Document: 0001493152-26-024454-index.html | 0001493152-26-024454 |
| Document: 0001493152-26-024454.txt | 0001493152-26-024454 |
| 8-K Data (Synthetic) | 0001493152-26-024454 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | S-1/A | — | awaiting T+20 | — | — |
May 29, 2026 21w ago | 8-K | $3.85 $3.10 | ▲ +19.48% | ▲ +18.18% | — |
May 21, 2026 22w ago | 8-K | $5.35 $3.18 | ▼ −40.52% | ▼ −40.85% | — |
May 19, 2026 22w ago | 8-K | $6.45 $3.39 | ▼ −47.44% | ▼ −48.18% | — |
May 19, 2026 22w ago | 8-K | $8.40 $3.70 | ▼ −55.95% | ▼ −56.94% | — |
May 18, 2026 23w ago | 8-K | $8.70 $3.69 | ▼ −57.59% | ▼ −59.17% | — |
May 8, 2026 24w ago | EFFECT | $4.21 $4.35 | ▼ −3.33% | ▼ −3.30% | — |
Apr 24, 2026 26w ago | 10-K/A | $6.23 $3.82 | ▲ +38.68% | ▲ +43.64% | — |
Apr 17, 2026 27w ago | 8-K | $6.60 $8.70 | ▲ +31.82% | ▲ +27.62% | — |
Apr 15, 2026 27w ago | S-3 | $7.37 $4.70 | ▼ −36.18% | ▼ −42.82% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers